A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/517 (2006.01) A61K 31/427 (2006.01) A61K 31/506 (2006.01) A61K 31/519 (2006.01) A61P 25/00 (2006.01) A61P 25/18 (2006.01) C12Q 1/68 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2745280
Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific in-hibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk vari-ation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified.
Linvention concerne des procédés de traitement des troubles du SNC tels que la schizophrénie, la psychose et les troubles cognitifs à laide dinhibiteurs spécifiques de lexpression et/ou de lactivité de la phosphatidylinositol-3-kinase p110 delta (PIK3CD). Linvention concerne également des procédés de détermination du risque de troubles du SNC et de la réponse au traitement. Linvention concerne une approche biologique des systèmes intégratifs pour identifier un mécanisme de signalement et un réseau génétique associés à la schizophrénie et à la variation du risque associé à la schizophrénie dans ErbB4. Une voie de RISK, associée à la variation génétique dErbB4 entraînant une augmentation de lexpression dun récepteur CYT-1 dErbB4 lié à PI3K et une enzyme PI3K spécifique, PIK3CD, a été identifiée.
Law Amanda J.
Weinberger Daniel R.
Departmen T. Of Health And Human Services The United States Of America As Represented By The Secretary
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Phosphatidylinositol-3-kinase p110 delta-targeted drugs in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphatidylinositol-3-kinase p110 delta-targeted drugs in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphatidylinositol-3-kinase p110 delta-targeted drugs in... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1438922